Recognition and treatment of autonomic disturbances in Parkinson’s disease

References

• Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinson’s disease. Mov Disord 2012;27(1):54-60
   PubMed Web of Science ®Google Scholar
• Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS [corrected] recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol 2013;20(1):16-34
   PubMed Web of Science ®Google Scholar
• Gallagher DA, Lees AJ, Schrag A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them? Mov Disord 2010;25(15):2493-500
   PubMed Web of Science ®Google Scholar
• Palma JA, Kaufmann H. Autonomic disorders predicting Parkinson’s disease. Parkinsonism Relat Disord 2014;20(Suppl 1):S94-8
   PubMedGoogle Scholar
• Fanciulli A, Strano S, Colosimo C, et al. The potential prognostic role of cardiovascular autonomic failure in alpha-synucleinopathies. Eur J Neurol 2013;20(2):231-5
   PubMed Web of Science ®Google Scholar
• Stubendorff K, Aarsland D, Minthon L, Londos E. The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson’s disease with dementia. PLoS ONE 2012;7(10):e45451
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Reichmann H. Cardiovascular autonomic dysfunction in Parkinson’s disease. J Neurol Sci 2010;289(1-2):74-80
   PubMed Web of Science ®Google Scholar
• Benarroch EE. Central autonomic control. In: Primer on the Autonomic Nervous System. In: Robertson D, editor. Academic Press; San Diego, USA: 2004. p. 17-28
   Google Scholar
• Robert W, Hamill RES. Peripheral autonomic nervous system. In: Primer on the Autonomic Nervous System. In: Robertson D, editor. Academic Press; San Diego, USA: 2004
   Google Scholar
• Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;24(2):197-211
   PubMed Web of Science ®Google Scholar
• Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010;119(6):689-702
   PubMed Web of Science ®Google Scholar
• Gelpi E, Navarro-Otano J, Tolosa E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov Disord 2014;29(8):1010-18
   PubMed Web of Science ®Google Scholar
• Ikemura M, Saito Y, Sengoku R, et al. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 2008;67(10):945-53
   PubMed Web of Science ®Google Scholar
• Del Tredici K, Braak H. Spinal cord lesions in sporadic Parkinson’s disease. Acta Neuropathol 2012;124(5):643-64
   PubMed Web of Science ®Google Scholar
• Alonso A, Huang X, Mosley TH, et al. Heart rate variability and the risk of Parkinson disease: the atherosclerosis risk in communities study. Ann Neurol 2015;77(5):877-83
   PubMed Web of Science ®Google Scholar
• Gilhus NE, Barnes MP, Brainin M. Late (Complicated) Parkinson’s Disease. In: European Handbook of Neurological Management. Wiley-Blackwell; Oxford, UK: 2010. p. 237-67
   Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011;26(Suppl 3):S42-80
   PubMed Web of Science ®Google Scholar
• Stemper B, Beric A, Welsch G, et al. Deep brain stimulation improves orthostatic regulation of patients with Parkinson disease. Neurology 2006;67(10):1781-5
   PubMed Web of Science ®Google Scholar
• Liu KD, Shan DE, Kuo TB, Yang CC. The effects of bilateral stimulation of the subthalamic nucleus on heart rate variability in patients with Parkinson’s disease. J Neurol 2013;260(7):1714-23
   PubMed Web of Science ®Google Scholar
• Sverrisdottir YB, Green AL, Aziz TZ, et al. Differentiated baroreflex modulation of sympathetic nerve activity during deep brain stimulation in humans. Hypertension 2014;63(5):1000-10
   PubMed Web of Science ®Google Scholar
• Ludwig J, Remien P, Guballa C, et al. Effects of subthalamic nucleus stimulation and levodopa on the autonomic nervous system in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007;78(7):742-5
   PubMed Web of Science ®Google Scholar
• Sumi K, Katayama Y, Otaka T, et al. Effect of subthalamic nucleus deep brain stimulation on the autonomic nervous system in Parkinson’s disease patients assessed by spectral analyses of R-R interval variability and blood pressure variability. Stereotact Funct Neurosurg 2012;90(4):248-54
   PubMed Web of Science ®Google Scholar
• Trachani E, Constantoyannis C, Sakellaropoulos GC, et al. Heart rate variability in Parkinson’s disease unaffected by deep brain stimulation. Acta Neurol Scand 2012;126(1):56-61
   PubMed Web of Science ®Google Scholar
• Fujishiro H, Frigerio R, Burnett M, et al. Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson’s disease. Mov Disord 2008;23(8):1085-92
   PubMed Web of Science ®Google Scholar
• Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European society of cardiology and the North American society of pacing and electrophysiology. Circulation 1996;93(5):1043-65
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Reichmann H. Cardiovascular autonomic testing in extrapyramidal disorders. J Neurol Sci 2011;310(1-2):129-32
   PubMed Web of Science ®Google Scholar
• Schmidt C, Berg D, Herting et al. Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. Mov Disord 2009;24(14):2136-42
   PubMed Web of Science ®Google Scholar
• Friedrich C, Rudiger H, Schmidt C, et al. Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. J Neural Transm 2008;115(11):1527-36
   PubMed Web of Science ®Google Scholar
• Friedrich C, Rudiger H, Schmidt C, et al. Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. Mov Disord 2010;25(3):315-24
   PubMed Web of Science ®Google Scholar
• Gasch J, Reimann M, Reichmann H, et al. Determination of baroreflex sensitivity during the modified Oxford maneuver by trigonometric regressive spectral analysis. PLoS ONE 2011;6(3):e18061
   PubMedGoogle Scholar
• Goldstein DS. Dysautonomia in Parkinson disease. Compr Physiol 2014;4(2):805-26
   PubMed Web of Science ®Google Scholar
• Goldstein DS. Orthostatic hypotension as an early finding in Parkinson’s disease. Clin Auton Res 2006;16(1):46-54
   PubMed Web of Science ®Google Scholar
• Low PA. Prevalence of orthostatic hypotension. Clin Auton Res 2008;18(Suppl 1):8-13
   PubMed Web of Science ®Google Scholar
• Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The consensus committee of the american autonomic society and the american academy of neurology. Neurology 1996;46(5):1470
   PubMed Web of Science ®Google Scholar
• Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011;21(2):69-72
   PubMed Web of Science ®Google Scholar
• Allcock LM, Kenny RA, Burn DJ. Clinical phenotype of subjects with Parkinson’s disease and orthostatic hypotension: autonomic symptom and demographic comparison. Mov Disord 2006;21(11):1851-5
   PubMed Web of Science ®Google Scholar
• Suzuki M, Urashima M, Oka H, et al. Cardiac sympathetic denervation in bradykinesia-dominant Parkinson’s disease. Neuroreport 2007;18(17):1867-70
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee KS, Song IU, et al. Cardiac sympathetic denervation is correlated with Parkinsonian midline motor symptoms. J Neurol Sci 2008;270(1-2):122-6
   PubMed Web of Science ®Google Scholar
• Kitayama M, Wada-Isoe K, Irizawa Y, Nakashima K. Association of visual hallucinations with reduction of MIBG cardiac uptake in Parkinson’s disease. J Neurol Sci 2008;264(1-2):22-6
   PubMed Web of Science ®Google Scholar
• Stuebner E, Vichayanrat E, Low DA, et al. Non-dipping nocturnal blood pressure and psychosis parameters in Parkinson disease. Clin Auton Res 2015;25(2):109-16
   PubMed Web of Science ®Google Scholar
• Oka H, Toyoda C, Yogo M, Mochio S. Olfactory dysfunction and cardiovascular dysautonomia in Parkinson’s disease. J Neurol 2010;257(6):969-76
   PubMed Web of Science ®Google Scholar
• Iijima M, Osawa M, Momose M, et al. Cardiac sympathetic degeneration correlates with olfactory function in Parkinson’s disease. Mov Disord 2010;25(9):1143-9
   PubMed Web of Science ®Google Scholar
• Kang P, Kloke J, Jain S. Olfactory dysfunction and parasympathetic dysautonomia in Parkinson’s disease. Clin Auton Res 2012;22(4):161-6
   PubMed Web of Science ®Google Scholar
• Postuma RB, Montplaisir J, Lanfranchi P, et al. Cardiac autonomic denervation in Parkinson’s disease is linked to REM sleep behavior disorder. Mov Disord 2011;26(8):1529-33
   PubMed Web of Science ®Google Scholar
• Nomura T, Inoue Y, Hogl B, et al. Relationship between (123)I-MIBG scintigrams and REM sleep behavior disorder in Parkinson’s disease. Parkinsonism Relat Disord 2010;16(10):683-5
   PubMed Web of Science ®Google Scholar
• Jain S, Siegle GJ, Gu C, et al. Autonomic insufficiency in pupillary and cardiovascular systems in Parkinson’s disease. Parkinsonism Relat Disord 2011;17(2):119-22
   PubMed Web of Science ®Google Scholar
• Oh YS, Kim JS, Yang DW, et al. Nighttime blood pressure and white matter hyperintensities in patients with Parkinson disease. Chronobiol Int 2013;30(6):811-17
   PubMed Web of Science ®Google Scholar
• Chiaravalloti A, Stefani A, Di Biagio D, et al. Cardiac sympathetic denervation is not related to nigrostriatal degeneration in Parkinson’s disease. Ann Nucl Med 2013;27(5):444-51
   PubMed Web of Science ®Google Scholar
• Oh YS, Kim JS, Chung YA, et al. Orthostatic hypotension, non-dipping and striatal dopamine in Parkinson disease. Neurol Sci 2013;34(4):557-60
   PubMed Web of Science ®Google Scholar
• Nakamura T, Hirayama M, Hara T, et al. Does cardiovascular autonomic dysfunction contribute to fatigue in Parkinson’s disease? Mov Disord 2011;26(10):1869-74
   PubMed Web of Science ®Google Scholar
• Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol 2014;71(4):499-504
   PubMed Web of Science ®Google Scholar
• Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 2012;27(5):617-26
   PubMed Web of Science ®Google Scholar
• Oguri T, Tachibana N, Mitake S, et al. Decrease in myocardial 123I-MIBG radioactivity in REM sleep behavior disorder: two patients with different clinical progression. Sleep Med 2008;9(5):583-5
   PubMed Web of Science ®Google Scholar
• Postuma RB, Iranzo A, Hogl B, et al. Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: A multicenter study. Ann Neurol 2015;77(5):830-9
   PubMed Web of Science ®Google Scholar
• Postuma RB, Gagnon JF, Bertrand JA, et al. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015;84(11):1104-13
   PubMed Web of Science ®Google Scholar
• Schmidt C, Herting B, Prieur S, et al. Valsalva manoeuvre in patients with different Parkinsonian disorders. J Neural Transm 2009;116(7):875-80
   PubMed Web of Science ®Google Scholar
• Reimann M, Schmidt C, Herting B, et al. Comprehensive autonomic assessment does not differentiate between Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. J Neural Transm 2010;117(1):69-76
   PubMed Web of Science ®Google Scholar
• Schmidt C, Herting B, Prieur S, et al. Autonomic dysfunction in patients with progressive supranuclear palsy. Mov Disord 2008;23(14):2083-9
   PubMed Web of Science ®Google Scholar
• Schmidt C, Herting B, Prieur S, et al. Autonomic dysfunction in different subtypes of multiple system atrophy. Mov Disord 2008;23(12):1766-72
   PubMed Web of Science ®Google Scholar
• Baschieri F, Calandra-Buonaura G, Doria A, et al. Cardiovascular autonomic testing performed with a new integrated instrumental approach is useful in differentiating MSA-P from PD at an early stage. Parkinsonism Relat Disord 2015;21(5):477-82
   PubMed Web of Science ®Google Scholar
• Pilleri M, Levedianos G, Weis L, et al. Heart rate circadian profile in the differential diagnosis between Parkinson disease and multiple system atrophy. Parkinsonism Relat Disord 2014;20(2):217-21
   PubMed Web of Science ®Google Scholar
• Braune S, Reinhardt M, Schnitzer R, et al. Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 1999;53(5):1020-5
   PubMed Web of Science ®Google Scholar
• Chung EJ, Lee WY, Yoon WT, et al. MIBG scintigraphy for differentiating Parkinson’s disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov Disord 2009;24(11):1650-5
   PubMed Web of Science ®Google Scholar
• Goldstein DS, Holmes C, Kopin IJ, Sharabi Y. Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. J Clin Invest 2011;121(8):3320-30
   PubMed Web of Science ®Google Scholar
• Kaufmann H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014;83(4):328-35
   PubMed Web of Science ®Google Scholar
• Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993;95(1):38-48
   PubMed Web of Science ®Google Scholar
• Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine study group. JAMA 1997;277(13):1046-51
   PubMed Web of Science ®Google Scholar
• Hauser RA, Isaacson S, Lisk JP, et al. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson’s disease (nOH306B). Mov Disord 2015;30(5):646-54
   PubMed Web of Science ®Google Scholar
• Treatment of orthostatic intolerance in patients with Parkinson’s disease using midodrine. Available from: https://clinicaltrials.gov/ct2/show/NCT02365012
   Google Scholar
• Durrieu G, Senard JM, Tran MA, et al. Effects of levodopa and bromocriptine on blood pressure and plasma catecholamines in parkinsonians. Clin Neuropharmacol 1991;14(1):84-90
   PubMed Web of Science ®Google Scholar
• Haapaniemi TH, Kallio MA, Korpelainen JT, et al. Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson’s disease. J Neurol 2000;247(11):868-74
   PubMed Web of Science ®Google Scholar
• Turkka J, Suominen K, Tolonen U, et al. Selegiline diminishes cardiovascular autonomic responses in Parkinson’s disease. Neurology 1997;48(3):662-7
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361(13):1268-78
   PubMed Web of Science ®Google Scholar
• Parkinson Study G. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-8
   PubMed Web of Science ®Google Scholar
• Korchounov A, Kessler KR, Schipper HI. Differential effects of various treatment combinations on cardiovascular dysfunction in patients with Parkinson’s disease. Acta Neurol Scand 2004;109(1):45-51
   PubMed Web of Science ®Google Scholar
• Perez-Lloret S, Rey MV, Fabre N, et al. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord 2012;18(5):501-5
   PubMed Web of Science ®Google Scholar
• Quadri R, Comino I, Scarzella L, et al. Autonomic nervous function in de novo parkinsonian patients in basal condition and after acute levodopa administration. Funct Neurol 2000;15(2):81-6
   PubMed Web of Science ®Google Scholar
• Sriranjini SJ, Ganesan M, Datta K, et al. Effect of a single dose of standard levodopa on cardiac autonomic function in Parkinson’s disease. Neurol India 2011;59(5):659-63
   PubMedGoogle Scholar
• Senard JM, Verwaerde P, Rascol O, Montastruc JL. Effects of acute levodopa administration on blood pressure and heart variability in never treated parkinsonians. Hypertens Res 1995;18(Suppl 1):S175-7
   PubMedGoogle Scholar
• Rocchi C, Pierantozzi M, Pisani V, et al. The impact of rotigotine on cardiovascular autonomic function in early Parkinson’s disease. Eur Neurol 2012;68(3):187-92
   PubMed Web of Science ®Google Scholar
• Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 2008;23(6):837-44
   PubMed Web of Science ®Google Scholar
• Barichella M, Cereda E, Madio C, et al. Nutritional risk and gastrointestinal dysautonomia symptoms in Parkinson’s disease outpatients hospitalised on a scheduled basis. Br J Nutr 2013;110(2):347-53
   PubMed Web of Science ®Google Scholar
• Shannon KM, Keshavarzian A, Dodiya HB, et al. Is alpha-synuclein in the colon a biomarker for premotor Parkinson’s disease? Evidence from 3 cases. Mov Disord 2012;27(6):716-19
   PubMed Web of Science ®Google Scholar
• Sanchez-Ferro A, Rabano A, Catalan MJ, et al. In vivo gastric detection of alpha-synuclein inclusions in Parkinson’s disease. Mov Disord 2015;30(4):517-24
   PubMed Web of Science ®Google Scholar
• Visanji NP, Marras C, Hazrati LN, et al. Alimentary, my dear Watson? The challenges of enteric alpha-synuclein as a Parkinson’s disease biomarker. Mov Disord 2014;29(4):444-50
   PubMed Web of Science ®Google Scholar
• Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS ONE 2010;5(1):e8762
   PubMed Web of Science ®Google Scholar
• Devos D, Lebouvier T, Lardeux B, et al. Colonic inflammation in Parkinson’s disease. Neurobiol Dis 2013;50:42-8
   PubMed Web of Science ®Google Scholar
• Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson’s disease. PLoS One 2011;6(12):e28032
   PubMed Web of Science ®Google Scholar
• Clairembault T, Leclair-Visonneau L, Neunlist M, Derkinderen P. Enteric glial cells: new players in Parkinson’s disease? Mov Disord 2015;30(4):494-8
   PubMed Web of Science ®Google Scholar
• Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson’s disease. Cochrane Database Syst Rev 2008(2):CD006564
   PubMed Web of Science ®Google Scholar
• Muller B, Assmus J, Larsen JP, et al. Autonomic symptoms and dopaminergic treatment in de novo Parkinson’s disease. Acta Neurol Scand 2013;127(4):290-4
   PubMed Web of Science ®Google Scholar
• Lee WY, Yoon WT, Shin HY, et al. Helicobacter pylori infection and motor fluctuations in patients with Parkinson’s disease. Mov Disord 2008;23(12):1696-700
   PubMed Web of Science ®Google Scholar
• Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol Dis 2012;46(3):559-64
   PubMed Web of Science ®Google Scholar
• Visanji NP, Marras C, Kern DS, et al. Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology 2015;84(6):609-16
   PubMed Web of Science ®Google Scholar
• Kalf JG, de Swart BJ, Bloem BR, Munneke M. Prevalence of oropharyngeal dysphagia in Parkinson’s disease: a meta-analysis. Parkinsonism Relat Disord 2012;18(4):311-15
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Autonomic dysfunction in Parkinson’s disease. Expert Rev Neurother 2012;12(6):697-706
   PubMed Web of Science ®Google Scholar
• Park H, Lee JY, Shin CM, et al. Characterization of gastrointestinal disorders in patients with parkinsonian syndromes. Parkinsonism Relat Disord 2015;21(5):455-60
   PubMed Web of Science ®Google Scholar
• Hammer MJ, Murphy CA, Abrams TM. Airway somatosensory deficits and dysphagia in Parkinson’s disease. J Parkinsons Dis 2013;3(1):39-44
   Google Scholar
• van Hooren MR, Baijens LW, Voskuilen S, et al. Treatment effects for dysphagia in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 2014;20(8):800-7
   PubMed Web of Science ®Google Scholar
• Troche MS, Brandimore AE, Foote KD, Okun MS. Swallowing and deep brain stimulation in Parkinson’s disease: a systematic review. Parkinsonism Relat Disord 2013;19(9):783-8
   PubMed Web of Science ®Google Scholar
• Simons JA, Fietzek UM, Waldmann A, et al. Development and validation of a new screening questionnaire for dysphagia in early stages of Parkinson’s disease. Parkinsonism Relat Disord 2014;20(9):992-8
   PubMed Web of Science ®Google Scholar
• Restivo DA, Palmeri A, Marchese-Ragona R. Botulinum toxin for cricopharyngeal dysfunction in Parkinson’s disease. N Engl J Med 2002;346(15):1174-5
   PubMed Web of Science ®Google Scholar
• Silbergleit AK, LeWitt P, Junn F, et al. Comparison of dysphagia before and after deep brain stimulation in Parkinson’s disease. Mov Disord 2012;27(14):1763-8
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010;74(11):924-31
   PubMed Web of Science ®Google Scholar
• Salat-Foix D, Andrews CN, Meddings J, Suchowersky O. Gastrointestinal symptoms in Parkinson disease: clinical aspects and management. Can J Neurol Sci 2011;38(4):557-64
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Fuchs G, Greulich W, et al. Treatment of dysautonomia in extrapyramidal disorders. J Neurol 2011;258(Suppl 2):S339-45
   PubMedGoogle Scholar
• Woitalla D, Kassubek J, Timmermann L, et al. Reduction of gastrointestinal symptoms in Parkinson’s disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial. Parkinsonism Relat Disord 2015;21(3):199-204
   PubMed Web of Science ®Google Scholar
• Gil RA, Hwynn N, Fabian T, et al. Botulinum toxin type A for the treatment of gastroparesis in Parkinson’s disease patients. Parkinsonism Relat Disord 2011;17(4):285-7
   PubMed Web of Science ®Google Scholar
• Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol 2003;2(2):107-16
   PubMed Web of Science ®Google Scholar
• Pagano G, Tan EE, Haider JM, et al. Constipation is reduced by beta-blockers and increased by dopaminergic medications in Parkinson’s disease. Parkinsonism Relat Disord 2015;21(2):120-5
   PubMed Web of Science ®Google Scholar
• Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001;57(3):456-62
   PubMed Web of Science ®Google Scholar
• Jennings D, Siderowf A, Stern M, et al. Imaging prodromal Parkinson disease: the Parkinson associated risk syndrome study. Neurology 2014;83(19):1739-46
   PubMed Web of Science ®Google Scholar
• Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov Disord 2007;22(9):1239-44
   PubMed Web of Science ®Google Scholar
• Sakakibara R, Panicker J, Finazzi-Agro E, Parkinson’s Disease Subcomittee TNPCiTICS. A guideline for the management of bladder dysfunction in Parkinson’s disease and other gait disorders. Neurourol Urodyn 2015
   PubMedGoogle Scholar
• Iacovelli E, Gilio F, Meco G, et al. Bladder symptoms assessed with overactive bladder questionnaire in Parkinson’s disease. Mov Disord 2010;25(9):1203-9
   PubMed Web of Science ®Google Scholar
• Kim M, Jung JH, Park J, et al. Impaired detrusor contractility is the pathognomonic urodynamic finding of multiple system atrophy compared to idiopathic Parkinson’s disease. Parkinsonism Relat Disord 2015;21(3):205-10
   PubMed Web of Science ®Google Scholar
• Badri AV, Purohit RS, Skenazy J, et al. A review of lower urinary tract symptoms in patients with Parkinson’s disease. Curr Urol Rep 2014;15(9):435
   PubMedGoogle Scholar
• Brusa L, Musco S, Bernardi G, et al. Rasagiline effect on bladder disturbances in early mild Parkinson’s disease patients. Parkinsonism Relat Disord 2014;20(8):931-2
   PubMed Web of Science ®Google Scholar
• Winge K, Nielsen KK, Stimpel H, et al. Lower urinary tract symptoms and bladder control in advanced Parkinson’s disease: effects of deep brain stimulation in the subthalamic nucleus. Mov Disord 2007;22(2):220-5
   PubMed Web of Science ®Google Scholar
• Herzog J, Weiss PH, Assmus A, et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson’s disease. Brain 2006;129(Pt 12):3366-75
   PubMed Web of Science ®Google Scholar
• Fritsche HM, Ganzer R, Schlaier J, et al. Acute urinary retention in two patients after subthalamic nucleus deep brain stimulation (STN-DBS) for the treatment of advanced Parkinson’s disease. Mov Disord 2009;24(10):1553-4
   PubMed Web of Science ®Google Scholar
• Zesiewicz TA, Evatt M, Vaughan CP, et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson’s disease. Parkinsonism Relat Disord 2015;21(5):514-20
   PubMed Web of Science ®Google Scholar
• A pilot study of mirabegron and behavioral modification including pelvic floor exercise for overactive bladder in parkinson’s disease (MAESTRO) (Maestro). Available from: https://clinicaltrials.gov/ct2/show/NCT02092181
   Google Scholar
• Vaughan CP, Juncos JL, Burgio KL, et al. Behavioral therapy to treat urinary incontinence in Parkinson disease. Neurology 2011;76(19):1631-4
   PubMed Web of Science ®Google Scholar
• Perissinotto MC, D’Ancona CA, Lucio A, et al. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. J Wound Ostomy Continence Nurs 2015;42(1):94-9
   PubMed Web of Science ®Google Scholar
• Stewart JD. Sexual function. In: Robertson D, editor. Primer on the Autonomic Nervous System. Academic Press; San Diego, USA: 2004. p. 116-17
   Google Scholar
• Meco G, Rubino A, Caravona N, Valente M. Sexual dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2008;14(6):451-6
   PubMed Web of Science ®Google Scholar
• Solla P, Bortolato M, Cannas A, et al. Paraphilias and paraphilic disorders in Parkinson’s disease: A systematic review of the literature. Mov Disord 2015;30(5):604-13
   PubMed Web of Science ®Google Scholar
• Wermuth L, Stenager E. Sexual problems in young patients with Parkinson’s disease. Acta Neurol Scand 1995;91(6):453-5
   PubMed Web of Science ®Google Scholar
• Celikel E, Ozel-Kizil ET, Akbostanci MC, Cevik A. Assessment of sexual dysfunction in patients with Parkinson’s disease: a case-control study. Eur J Neurol 2008;15(11):1168-72
   PubMed Web of Science ®Google Scholar
• Bronner G, Vodusek DB. Management of sexual dysfunction in Parkinson’s disease. Ther Adv Neurol Disord 2011;4(6):375-83
   PubMedGoogle Scholar
• Jitkritsadakul O, Jagota P, Bhidayasiri R. Postural instability, the absence of sexual intercourse in the past month, and loss of libido are predictors of sexual dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2015;21(1):61-7
   PubMed Web of Science ®Google Scholar
• Wullner U, Schmitz-Hubsch T, Antony G, et al. Autonomic dysfunction in 3414 Parkinson’s disease patients enrolled in the German Network on Parkinson’s disease (KNP e.V.): the effect of ageing. Eur J Neurol 2007;14(12):1405-8
   PubMed Web of Science ®Google Scholar
• Yamashita S, Uchida Y, Kojima S, et al. Heatstroke in patients with Parkinson’s disease. Neurol Sci 2012;33(3):685-7
   PubMed Web of Science ®Google Scholar
• Sehara Y. Hypothermia with Osborn waves in Parkinson’s disease. Intern Med 2009;48(8):615-18
   PubMed Web of Science ®Google Scholar
• Mikihiro Kihara JS, Phillip A. Low Temperature regulation. In: Robertson D, editor. Primer on the Autonomic Nervous System. Academic Press; San Diego, USA: 2004. p. 127-9
   Google Scholar
• Michell AW, Luheshi LM, Barker RA. Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson’s disease. Neurosci Lett 2005;381(3):294-8
   PubMed Web of Science ®Google Scholar
• Dabby R, Djaldetti R, Shahmurov M, et al. Skin biopsy for assessment of autonomic denervation in Parkinson’s disease. J Neural Transm 2006;113(9):1169-76
   PubMed Web of Science ®Google Scholar
• Doppler K, Ebert S, Uceyler N, et al. Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology. Acta Neuropathol 2014;128(1):99-109
   PubMed Web of Science ®Google Scholar
• Zhong G, Bolitho S, Grunstein R, et al. The relationship between thermoregulation and REM sleep behaviour disorder in Parkinson’s disease. PLoS One 2013;8(8):e72661
   PubMedGoogle Scholar
• Giza E, Katsarou Z, Georgiadis G, Bostantjopoulou S. Sympathetic skin response in Parkinson’s disease before and after mental stress. Neurophysiol Clin 2012;42(3):125-31
   PubMed Web of Science ®Google Scholar
• Asahina M, Mathias CJ, Katagiri A, et al. Sudomotor and cardiovascular dysfunction in patients with early untreated Parkinson’s disease. J Parkinsons Dis 2014;4(3):385-93
   Google Scholar
• Kawada M, Tamada Y, Simizu H, et al. Reduction in QSART and vasoactive intestinal polypeptide expression in the skin of Parkinson’s disease patients and its relation to dyshidrosis. J Cutan Pathol 2009;36(5):517-21
   PubMed Web of Science ®Google Scholar
• Kikkawa Y, Asahina M, Suzuki A, Hattori T. Cutaneous sympathetic function and cardiovascular function in patients with progressive supranuclear palsy and Parkinson’s disease. Parkinsonism Relat Disord 2003;10(2):101-6
   PubMed Web of Science ®Google Scholar
• Sanghera MK, Ward C, Stewart RM, et al. Alleviation of drenching sweats following subthalamic deep brain stimulation in a patient with Parkinson’s disease–a case report. J Neurol Sci 2009;285(1-2):246-9
   PubMed Web of Science ®Google Scholar
• McDougal DH, Gamlin PD. Autonomic control of the eye. Compr Physiol 2015;5(1):439-73
   PubMed Web of Science ®Google Scholar
• Schmidt C, Herting B, Prieur S, et al. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. Mov Disord 2007;22(14):2123-6
   PubMed Web of Science ®Google Scholar
• Stergiou V, Fotiou D, Tsiptsios D, et al. Pupillometric findings in patients with Parkinson’s disease and cognitive disorder. Int J Psychophysiol 2009;72(2):97-101
   PubMed Web of Science ®Google Scholar
• Sawada H, Yamakawa K, Yamakado H, et al. Cocaine and phenylephrine eye drop test for Parkinson disease. JAMA 2005;293(8):932-4
   PubMed Web of Science ®Google Scholar
• Hori N, Takamori M, Hirayama M, et al. Pupillary supersensitivity and visual disturbance in Parkinson’s disease. Clin Auton Res 2008;18(1):20-7
   PubMed Web of Science ®Google Scholar
• Granholm E, Morris S, Galasko D, et al. Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer’s and Parkinson’s disease. Int J Psychophysiol 2003;47(2):95-115
   PubMed Web of Science ®Google Scholar
• Jain S, Siegle GJ, Gu C, et al. Pupillary unrest correlates with arousal symptoms and motor signs in Parkinson disease. Mov Disord 2011;26(7):1344-7
   PubMed Web of Science ®Google Scholar
• Tijero B, Gomez Esteban JC, Somme J, et al. Autonomic dysfunction in parkinsonian LRRK2 mutation carriers. Parkinsonism Relat Disord 2013;19(10):906-9
   PubMed Web of Science ®Google Scholar
• Tijero B, Gabilondo I, Lezcano E, et al. Autonomic involvement in Parkinsonian carriers of PARK2 gene mutations. Parkinsonism Relat Disord 2015;21(7):717-22
   PubMed Web of Science ®Google Scholar
• Mansfield KJ. Role of fesoterodine in the treatment of overactive bladder. Open Access J Urol 2009;2:1-9
   Google Scholar